Camurati-Engelmann Disease with Good Treatment Response to Losartan.

Indian J Nucl Med

Department of General Medicine, M.E.S. Medical College, Malappuram, Kerala, India.

Published: January 2019

Camurati-Engelmann disease (CED) or progressive diaphyseal dysplasia is a rare autosomal dominant inherited condition which belongs to the group of craniotubular hyperostosis. A 24-year-old man presented with insidious onset, progressive pain over both legs, and forearms for 3 years. He was born as the second child of a nonconsanguineous union by vaginal delivery at term without any complications. The clinical, radiological, and histopathological features were suggestive of CED. Transforming growth factor-β1 sequence analysis revealed a missense mutation (c.652C>T; p. Arg218Cys) confirming the diagnosis. He had a good response to treatment with Losartan. CED should be considered in the differential diagnosis of patients presenting with nonspecific limb pains and radiological features of skeletal dysplasia. Early recognition and diagnosis play a crucial role in management. This case discuss regarding the potential benefits of the drug losartan in the management of a rare bone disease for which the evidence from previous literature is scarce.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593949PMC
http://dx.doi.org/10.4103/ijnm.IJNM_44_19DOI Listing

Publication Analysis

Top Keywords

camurati-engelmann disease
8
disease good
4
good treatment
4
treatment response
4
response losartan
4
losartan camurati-engelmann
4
disease ced
4
ced progressive
4
progressive diaphyseal
4
diaphyseal dysplasia
4

Similar Publications

Sclerosing bone dysplasias encompass abnormalities in bone density, divided into hereditary and nonhereditary forms. Primarily diagnosed through radiography, they are often incidental findings. Among the hereditary forms, the following stand out: osteopetrosis, osteopoikilosis, multiple diaphyseal sclerosis (ribbing disease), osteopathia striata, and Camurati-Engelmann disease.

View Article and Find Full Text PDF

Background: Camurati-Engelmann disease (CED) is an extremely rare autosomal dominant genetic disorder that can cause increased intracranial pressure (ICP) secondary to cranial hyperostosis, which decreases intracranial volume. Surgical procedures to reduce ICP in medically refractory cases include intracranial volume expansion and ventriculoperitoneal shunting.

Observations: The authors present the case of a pediatric patient with CED and medically refractory increased ICP who underwent unilateral hemicraniectomy with titanium cranioplasty, resulting in a complete long-term resolution of symptoms.

View Article and Find Full Text PDF

Phenotypic Variability in Camurati-Engelmann Disease: A Case Report of a Family with the c.653G>A Pathogenic Variant in the Gene.

Genes (Basel)

October 2024

Replicon Research Nucleus, Graduate Program in Genetics, School of Medical and Life Sciences, Pontifical Catholic University of Goiás, Goiânia 74605-050, GO, Brazil.

Camurati-Engelmann Disease (CED), or Progressive Diaphyseal Dysplasia, is a rare autosomal dominant disorder caused by heterozygous mutations in the Gene, essential for bone regeneration. This study examines the genotype-phenotype relationship in a family diagnosed with CED, specifically focusing on a missense variant (c.653G>A, p.

View Article and Find Full Text PDF
Article Synopsis
  • Camurati-Engelmann disease (CED) is a rare genetic illness that makes long bones in the body grow thicker than normal, causing pain and trouble walking.
  • A 30-month-old boy was found to have CED after initial treatments for a different condition didn't work, and special tests showed changes in his TGFB-1 gene.
  • Since CED is rare and can show different symptoms, doctors need to be careful and think of it when diagnosing patients to help manage their symptoms better.
View Article and Find Full Text PDF
Article Synopsis
  • - Camurati-Engelmann disease (CED) is a genetic bone disorder categorized into two types based on TGFB1 mutations, where CED2 lacks these mutations.
  • - In this study, researchers discovered two new mutations in the TGFB2 gene in CED2 patients, which affect a specific region of the gene, potentially leading to increased TGF-β2 activity and bone formation.
  • - The findings indicate that CED2 may result from heightened TGF-β2 signaling due to a loss of regulatory functions of the latency-associated peptide (LAP), highlighting distinct roles of TGFB1 and TGFB2 in bone development.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!